Zai Lab
Maria Tea, MD, PD has a diverse work experience in the medical field. From 2021 to the present, they have been working at Zai Lab, initially as a Medical Director and later promoted to Senior Medical Director. Prior to that, they were associated with the Medical University of Vienna from 2004 to 2021, where they held the position of Associate Professor and Head of Outpatient Clinic HBOC. Maria also obtained the title of PD (Privat Dozent) through the habilitation process during their tenure at the university. In 2011, they worked as a Visiting Fellow at MD Anderson Cancer Center, and in 2009, they served as a Breast Fellow at Fudan University Shanghai Cancer Center. Maria also gained experience as a Volunteer and Fundraiser at the Foundation for Breast Health from 2004 to 2007.
Maria Tea, MD, PD studied at the Medical University of Vienna from 1998 to 2004, where they received their Doctor of Medicine (M.D.) degree. Maria also holds certifications in Medical Genetics, Obstetrics and Gynecology, and is a Licensed Clinical Investigator.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.